<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638660</url>
  </required_header>
  <id_info>
    <org_study_id>OPI-NYXDLD-301 (LYNX-1)</org_study_id>
    <nct_id>NCT04638660</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA)&#xD;
           in subjects with Dim Light Vision Disturbances (DLD)&#xD;
&#xD;
        -  To evaluate efficacy of Nyxol to improve visual performance&#xD;
&#xD;
        -  To evaluate the safety of Nyxol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo-controlled, double-masked, multiple-dose, Phase 3 study in approximately 160&#xD;
      randomized subjects with DLD (approximately 136 that are evaluable for efficacy), evaluating&#xD;
      safety and efficacy of Nyxol in subjects with DLD following administration of Nyxol once&#xD;
      daily (QD) at or near bedtime (at 8PM to 10PM) in both eyes (OU) for 14 days.&#xD;
&#xD;
      Following the successful completion of screening, each subject will be stratified by iris&#xD;
      color (light/dark irides) and will then be randomized to treatment (masked) 1:1, Nyxol or&#xD;
      placebo (vehicle).&#xD;
&#xD;
      Treatment (Nyxol or placebo) will be administered in both eyes (OU) by the subjects at or&#xD;
      near bedtime each day.&#xD;
&#xD;
      At the first visit subjects will be screened for study eligibility.&#xD;
&#xD;
      Treatment visits will occur 2 times: Day 8 (+1 day)/Visit 2 and Day 15 (+1 day)/Visit 3.&#xD;
      mLCVA evaluations shall be performed on each of these days.&#xD;
&#xD;
      A follow-up visit (Visit 4) phone call will occur 1 to 3 days after Visit 3.&#xD;
&#xD;
      At select sites OPD Scan measurements will be made using wavefront abhermettry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will be randomized into the study in a 1:1 ratio to one of the treatment arms (Nyxol or placebo), with a stratification by light/dark irides.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with 3 lines mLCVA improvement in study eye</measure>
    <time_frame>8 days</time_frame>
    <description>Percent of subjects with ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (≥3 lines) of improvement in the study eye compared to baseline in monocular mLCVA at Day 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with mLCVA improvement</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in mLCVA at Day 8 (excluding the primary endpoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with photopic low contrast visual acuity (pLCVA) and mHCVA improvement</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in pLCVA and mHCVA at Day 8 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline in mLCVA, pLCVA, mesopic high contrast visual acuity (mHCVA) and distance corrected near visual acuity (DCNVA)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Change and percent change from baseline in mLCVA, pLCVA, mHCVA and DCNVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline in pupil diameter (PD)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Change and percent change from baseline in PD</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change and percent change in total RMS error and higher-order RMS</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Change and percent change from baseline in total RMS error (score) and higher-order RMS (spherical, coma, trefoil) error under mesopic conditions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dim Light Vision Disturbances</condition>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in both eyes at or near bedtime (8PM to 10PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in both eyes at or near bedtime (8PM to 10PM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution 0.75%</intervention_name>
    <description>0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist</description>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <other_name>Nyxol</other_name>
    <other_name>Nyxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution Vehicle (Placebo)</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 18 years of age&#xD;
&#xD;
          2. Subject-reported DLD (likely subjects with a history of multifocal IOLs,&#xD;
             post-laser-assisted in situ keratomileusis [LASIK], corneal scars, and keratoconus)&#xD;
&#xD;
          3. Ability to comply with all protocol-mandated procedures independently and to attend&#xD;
             all&#xD;
&#xD;
          4. Otherwise healthy and well-controlled subjects&#xD;
&#xD;
          5. Able and willing to give written consent to participate in this study&#xD;
&#xD;
          6. Able to self-administer study medication&#xD;
&#xD;
          7. PD ≥ 6 mm under mesopic conditions (prior to illumination) in at least one eye&#xD;
&#xD;
          8. ≤ 20 (20/100 Snellen or worse) ETDRS letters in mLCVA score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          1. Prior history of dry eye diagnosis, taking prescription drops for dry eye, or taking&#xD;
             artificial tear drops occasionally for dry eye&#xD;
&#xD;
          2. Prior history of fluctuating vision&#xD;
&#xD;
          3. Clinically significant ocular disease as deemed by the Investigator that might&#xD;
             interfere with the study&#xD;
&#xD;
          4. Known hypersensitivity to any topical alpha-adrenoceptor antagonists&#xD;
&#xD;
          5. Known allergy or contraindication to any component of the vehicle formulation&#xD;
&#xD;
          6. History of cauterization of the punctum or punctal plug (silicone or collagen)&#xD;
             insertion or removal&#xD;
&#xD;
          7. Ocular trauma, ocular surgery (e.g., IOLs) or laser procedure (e.g., LASIK,&#xD;
             photorefractive keratectomy [PRK]) within 6 months prior to screening&#xD;
&#xD;
          8. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of&#xD;
             any kind within 7 days of screening&#xD;
&#xD;
          9. Recent or current evidence of ocular infection or inflammation in either eye. Subjects&#xD;
             must be symptom free for at least 7 days.&#xD;
&#xD;
         10. History of diabetic retinopathy, diabetic macular edema, or dry or wet macular&#xD;
             degeneration&#xD;
&#xD;
         11. History of any traumatic (surgical or nonsurgical) or nontraumatic condition affecting&#xD;
             the pupil or iris&#xD;
&#xD;
         12. Unwilling or unable to discontinue use of contact lenses at screening until study&#xD;
             completion, except for keratoconus subjects who may wear contacts up to 24 hours prior&#xD;
             to their scheduled visits&#xD;
&#xD;
        Systemic:&#xD;
&#xD;
          1. Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor&#xD;
             antagonists&#xD;
&#xD;
          2. Clinically significant systemic disease that might interfere with the study&#xD;
&#xD;
          3. Initiation of treatment with or any changes to the current dosage, drug, or regimen of&#xD;
             any systemic adrenergic or cholinergic drugs within 7 days prior to screening or&#xD;
             during the study&#xD;
&#xD;
          4. Participation in any investigational study within 30 days prior to screening and&#xD;
             during the conduct of the study&#xD;
&#xD;
          5. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable form of birth control&#xD;
&#xD;
          6. Resting HR outside the specified range (50-110 beats per minute)&#xD;
&#xD;
          7. Hypertension with resting diastolic BP &gt; 105 mmHg or systolic BP &gt; 160 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Drey Coleman</last_name>
    <phone>248-681-9815</phone>
    <email>dcoleman@ocuphire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site 6</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 1</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 17</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 3</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 18</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 21</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 13</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 20</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 14</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>41008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 7</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63690</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 10</name>
      <address>
        <city>Palisades Park</city>
        <state>New Jersey</state>
        <zip>07650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 8</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 4</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 22</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 9</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 2</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 12</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Test 15</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 11</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 5</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 19</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site 16</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nyxol, Night Vision Disturbances, Glare, Halos, Starbursts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

